A new HIV drug has passed its first human clinical trial.
At end of the trial, it was discovered that the drug, named Gammora, created by Zion Medical, an Israeli biotech company was capable of wiping out 99 per cent of HIV infected cells in the human body.
According to a statement released by the company and available on PR Newswire, Gammora was able to eliminate up to 90 per cent of the virus during the first four weeks of the trial.
Zion Medical developed the drug Gammora in collaboration with the Hebrew University in Jerusalem and the Sirion Biotech in Germany.
The drug is designed to attack and kill the HIV-infected cells in the human body without causing damage to the healthy cells.
In the study, researchers randomly assigned nine participating patients from the Ronald Bata Memorial Hospital in Uganda to receive different doses of Gammora between four to five weeks in July and August of this year.
While the new HIV drug is still in its first stage of exploration, the results have already offered hope that a cure for the dreaded virus is possible.
“Most patients showed a significant reduction of the viral load of up to 90 per cent from the baseline during the first four weeks,” said Dr. Esmira Naftalim, Zion Medical’s head of development.
Made In Israel. Tested On Africans.
“These first clinical results were beyond our expectations and promise hope in finding a cure for the disease,” Dr Esmira Naftali, head of development at Zion Medical, said, adding that nine patients at Ronald Bata Memorial Hospital in Uganda were randomly assigned to receive different doses of the drug for four to five weeks.
In the second part of the trial done two weeks later, patients were given the drug with additional retroviral treatment after four to five weeks.
Patients received either lopinavir 800 mg and ritonavir 200 mg (LPV+r) daily in combination with Gammora administered twice a week, or LPV+r only.
The results showed that the combined treatments eliminated up to 99 per cent of the viral load within four weeks without exhibiting any side effects.
During the 10-week study, patients in both groups showed a significant increase in T-cell count — another name for CD4 cells, which play a role in the body’s immune system.
The drug is derived from HIV enzyme integrate that is responsible for inserting the virus’s genetic material into the DNA of the infected cell.
There are indications that 1,493,382 Kenyans live with the virus, with the overall prevalence rate dropping to 4.8 per cent. (Source)